ERBB2 and breast carcinoma: Specific tumor biologic features, gradually integrated into the pathological assessment over time, such as hormone receptor status [10] or human epidermal growth factor receptor 2 (HER2) expression for patients with breast cancer [11], and microsatellite instability (MSI) assessment in colorectal cancer [12, 13], also became guiding factors for adjuvant treatment decisions.